Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...

Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

If you’re considering a semaglutide medication like Ozempic or Wegovy for weight loss, you may be a bit worried about the ...

After years in shortage, weight loss and diabetes drugs Ozempic and Wegovy are now considered to be “available” by the Food ...

You may have heard about — or maybe even experienced — the short-term side effects of Ozempic® — such as nausea, vomiting, ...

All doses of Novo Nordisk’s (NVO) diabetes and obesity treatments are listed as available on the FDA’s drug shortage list as of ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

Previously, the lowest dose of Wegovy, 25 milligrams, was listed as in short supply. Since early 2022, several doses of semaglutide — the active ingredient in Wegovy and Ozempic — had been on the ...

Just over a year ago, New Zealand customs officials started to intercept batches of injectable medications labelled Fitaro ...

Both Ozempic and Wegovy are forms of semaglutide, a GLP-1 agonist drug manufactured by Novo Nordisk. When reached for comment ...